DOI QR코드

DOI QR Code

CD44 and CD133 as Cancer Stem Cell Markers for Gastric Cancer

  • Lee, Hyun-Joo (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Choi, Young-Sil (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Sung-Joo (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Moon, Hyoun-Jong (Department of Surgery, Myongji Hospital, Kwandong University College of Medicine)
  • Received : 2010.06.04
  • Accepted : 2010.07.26
  • Published : 2010.09.30

Abstract

Purpose: Currently, the two most influential gastric stem cell marker candidates are CD44 and CD133. The aim of this study was to make a comparison and determine the appropriate marker for use in gastric cancer stem cell research. Materials and Methods: We analyzed the expressions of CD44, CD133, and CD24 from the gastric cancer cell lines MKN45, MKN74, KATO-III, NCI-N87, SNU-1, SNU-216, SNU-601, SNU-638, and SNU-688 using flow cytometry. In addition, we measured the change in viability after applying 5 fluorouracil (5-FU) to the MKN45, MKN74, KATO-III, and NCI-N87 cell lines using a Cell Counting Kit 8. Results: CD133 expression was above moderate in the KATO-III, SNU-216, SNU-601 cell lines, whereas it was below 1% in the remaining cell lines. CD44 was expressed at levels above 5% in all gastric cancer cell lines. The effect of 5-FU on viability and CD133 or CD44 expression in the cell lines were not related. Conclusions: Expression of CD133 positive cells was insufficient in the gastric cancer cell lines. Therefore, of the cell lines tested, CD44 was the most appropriate tumor maker for research on gastric cancer stem cells.

Acknowledgement

Supported by : BumSuk Academic Research Fund

References

  1. Dick JE, Bhatia M, Gan O, Kapp U, Wang JC. Assay of human stem cells by repopulation of NOD/SCID mice. Stem Cells 1997;15(Suppl 1):199-203.
  2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988. https://doi.org/10.1073/pnas.0530291100
  3. Dick JE. Stem cells: self-renewal writ in blood. Nature 2003;423:231-233. https://doi.org/10.1038/423231a
  4. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identifi cation of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009;27:1006-1020. https://doi.org/10.1002/stem.30
  5. Huang P, Wang CY, Gou SM, Wu HS, Liu T, Xiong JX. Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World J Gastroenterol 2008;14:3903-3907. https://doi.org/10.3748/wjg.14.3903
  6. Li C, Lee CJ, Simeone DM. Identifi cation of human pancreatic cancer stem cells. Methods Mol Biol 2009;568:161-173. https://doi.org/10.1007/978-1-59745-280-9_10
  7. Ha TK, Kwon SJ. Clinicopathologic characteristics according to the type of recurrence in curtively-resected gastric cancer patients. J Korean Gastric Cancer Assoc 2007;7:23-30.
  8. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identifi cation of human brain tumour initiating cells. Nature 2004;432:396-401. https://doi.org/10.1038/nature03128
  9. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodefi cient mice. Nature 2007; 445:106-110. https://doi.org/10.1038/nature05372
  10. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006;351:820-824. https://doi.org/10.1016/j.bbrc.2006.10.128
  11. Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Pri sco MG, et al. Cells with characteristics of cancer stem/pro genitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 2009;15:4299-4311. https://doi.org/10.1158/1078-0432.CCR-08-1883
  12. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, et al. Identifi cation of cancer stem cells in Ewing's sarcoma. Cancer Res 2009;69:1776-1781. https://doi.org/10.1158/0008-5472.CAN-08-2242
  13. Friedman S, Lu M, Schultz A, Thomas D, Lin RY. CD133+ anaplastic thyroid cancer cells initiate tumors in immuno-deficient mice and are regulated by thyrotropin. PLoS One 2009;4:e5395. https://doi.org/10.1371/journal.pone.0005395
  14. Eramo A, Lotti F, Sette G, Pilozzi E, Biff oni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Diff er 2008;15:504-514. https://doi.org/10.1038/sj.cdd.4402283
  15. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100-109. https://doi.org/10.1038/sj.bjc.6604437
  16. Boegl M, Prinz C. CD133 expression in different stages of gastric adenocarcinoma. Br J Cancer 2009;100:1365-1366. https://doi.org/10.1038/sj.bjc.6605001
  17. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 2008;118:2021-2024.
  18. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008;18:2111-2120.
  19. Hsieh HF, Yu JC, Ho LI, Chiu SC, Harn HJ. Molecular studies into the role of CD44 variants in metastasis in gastric cancer. Mol Pathol 1999;52:25-28. https://doi.org/10.1136/mp.52.1.25
  20. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A 2010;107:3722-3727. https://doi.org/10.1073/pnas.0915135107
  21. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-765. https://doi.org/10.1038/sj.bjc.6604242
  22. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancerinitiating cells from primary human tumors. Cancer Res 2008;68:4311-4320. https://doi.org/10.1158/0008-5472.CAN-08-0364
  23. Yook JH, Choi WY, Shin DG, Kim YJ, Kim JS, Oh ST, et al. Expression of E-cardherin and CD44H in bormann type IV gastric cancer. J Korean Gastric Cancer Assoc 2004;4:82-88. https://doi.org/10.5230/jkgca.2004.4.2.82
  24. Mirecka J, Marx D, Schauer A. Immunohistochemical localization of CD44 variants 5 and 6 in human gastric mucosa and gastric cancer. Anticancer Res 1995;15:1459-1465.
  25. Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, et al. CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 2010;101:673-678. https://doi.org/10.1111/j.1349-7006.2009.01430.x
  26. Nishii T, Yashiro M, Shinto O, Sawada T, Ohira M, Hirakawa K. Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci 2009;100:1397-1402. https://doi.org/10.1111/j.1349-7006.2009.01211.x
  27. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009;69:1951-1957. https://doi.org/10.1158/0008-5472.CAN-08-2023
  28. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 2009;125:2323-2331. https://doi.org/10.1002/ijc.24573